Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle

Immune checkpoint blockade (ICB) therapy has shifted the paradigm for cancer treatment. However, the majority of patients lack effective responses because of the emergence of immune-refractory tumors that disrupt the amplification of antitumor immunity. Therefore, the identification of clinically av...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Se Jin, Lee, Hyo-Jung, Song, Kwon-Ho, Kim, Suyeon, Cho, Eunho, Lee, Jaeyoon, Bosenberg, Marcus W., Kim, Tae Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920337/
https://www.ncbi.nlm.nih.gov/pubmed/35104240
http://dx.doi.org/10.1172/JCI147908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920337/
https://www.ncbi.nlm.nih.gov/pubmed/35104240
http://dx.doi.org/10.1172/JCI147908

Ejemplares similares